Trial Profile
A Study to Evaluate the Diagnostic Yield of Biopsies and Compare the Effect of Bortezomib With Other Therapeutic Strategies in Advanced Cardiac Light Chain Amyloidosis (ACAL) Patients
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 26 Apr 2016
Price :
$35
*
At a glance
- Drugs Bortezomib (Primary)
- Indications Amyloidosis
- Focus Pharmacodynamics; Therapeutic Use
- 26 Apr 2016 New trial record
- 17 Mar 2016 Results published in the Journal of Heart and Lung Transplantation